Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20

4:51

Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.

Diffuse Large B Cell Lymphoma
Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20

Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.

Diffuse Large B Cell Lymphoma Similar Videos

Similar Videos